Established in August 2003, Harbin Longsheng Beiyao Bio-engineering Co., Ltd. is located in Harbin, the beautiful ice city known as the "Little Paris of the East." Adhering to the business philosophy of "leading modern pharmaceutical technology and promoting the national health industry," the company has maintained consistent quality for over 20 years, with two generations striving forward. It has grown from an initial edible fungus seed research and development company to a high-tech enterprise integrating R&D, production, and sales of a full-industry-chain drug traceability system. The company has acquired two local pharmaceutical companies, gradually developing from an initial asset of 2 million yuan to a modern pharmaceutical production enterprise with assets of nearly 200 million yuan and annual sales exceeding 100 million yuan. The company has a registered capital of 56.4 million yuan, covers an area of approximately 50,000 square meters, and has over 300 employees, including junior, intermediate, and senior technical personnel and personnel in various positions.

The company currently has six dosage forms: tablets, capsules, granules, oral solutions, syrups, and mixtures; and 68 national drug approval numbers, including 11 traditional Chinese medicine varieties. Major products include Pudi Lan Anti-inflammatory Tablets, Yi Nao Ning Tablets, Hirudo Blood Circulation Capsules, and Tongmai Ciwujia Capsules; and 57 chemical drugs, including Cefdinir Dispersible Tablets, Cefaclor Dispersible Tablets, and Ibuprofen Syrup. Hirudo Blood Circulation Capsules and Tongmai Ciwujia Capsules are exclusive national products. The company has 1 invention patent, 8 utility model patents, 17 design patents, 8 copyrights, and over 20 registered trademarks.

In the future, the company will adhere to the principles of selecting high-quality medicinal materials and operating as a conscientious enterprise, upholding the development philosophy of "Longsheng Beiyao, only making good medicine." It will strictly implement the five basic principles of "good material selection, good process, good quality control, good efficacy, and good service." With the mission of caring for life and benefiting health, the company will integrate its advantageous resources to focus on developing a combination of cardiovascular products and antibacterial and anti-inflammatory products (both traditional Chinese and Western medicine), expand sales markets, build the Longjiang pharmaceutical brand, achieve the perfect combination of traditional medicine theory and modern technology, and grow the Longjiang pharmaceutical industry. In 2023, the company achieved sales revenue of 159,962,800 yuan and taxes and profits of 16,934,300 yuan.

Lawyer Profile